Research programme: M3 muscarinic receptor antagonists - Chiesi Farmaceutici/SALVATAlternative Names: CHF-5407; SVT-47060
Latest Information Update: 31 May 2010
At a glance
- Originator SALVAT
- Mechanism of Action Muscarinic M3 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Chronic obstructive pulmonary disease
Most Recent Events
- 02 Nov 2006 Preclinical trials in Chronic obstructive pulmonary disease (unspecified route)